What Perventil Treats — Main Uses and Benefits

The primary therapeutic role of this medication is to provide supportive relief when symptoms interfere with routine activities. It is applied across domains where additional symptomatic support is needed, primarily to help manage episodes of difficulty breathing, wheezing, shortness of breath, and chest tightness. This medication is commonly used to address symptoms related to physical discomfort in conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

Targeted Symptom Relief

This medication is used in situations involving certain distressing symptoms. It is applied in clinical settings that involve acute or unstable symptom patterns and in situations requiring temporary assistance in symptom stabilization, such as sudden attacks or Exercise-Induced Bronchospasm (EIB). The goal is to support patients during episodes of heightened discomfort, which helps maintain a sense of stability when symptoms are more noticeable. It is relevant for easing symptoms that interfere with daily comfort during difficult episodes, providing supportive relief when symptoms become temporarily overwhelming.

---

Quick Fact: Support for Acute Respiratory Symptoms

Regulatory References

1. NIH MedlinePlus overview

Perventil, which contains albuterol sulfate, is an inhalation aerosol medicine with specific eligibility requirements strictly defined by regulatory agencies.

Eligibility and Exclusion Criteria

Classification	Populations Covered
Eligible Population	Adults and pediatric patients aged 4 years and older.
Contraindicated Use	Patients with a history of hypersensitivity (allergic reaction) to albuterol or to any other ingredients within the specific Perventil HFA formulation.
Use Not Established	Safety and effectiveness have not been established in pediatric patients younger than 4 years of age.

Regulatory Basis for Use

Official government labeling, such as the FDA Prescribing Information, establishes the two core constraints on Perventil use. The primary absolute contraindication is any prior allergic reaction to the drug or its components. This dictates an immediate and permanent exclusion from use. The second constraint is the age minimum of 4 years, below which the drug's safety and effectiveness are not established, meaning use in this younger population is not officially permitted.

Perventil Interactions with other medicines and products

The interaction profile for Perventil is defined by officially documented interactions related to its dual components, Theophylline and Salbutamol (Albuterol).

Interaction Scope and Restrictions

Category	Official Regulatory Statement
Medicinal products explicitly contraindicated	Non-selective beta-Adrenergic Receptor Blockers (e.g., Propranolol) are formally contraindicated with Salbutamol as they oppose the bronchodilator effect and may precipitate severe bronchospasm.
Metabolic Clearance Interference (PK)	Strong CYP450 1A2 Inhibitors (e.g., Ciprofloxacin, Cimetidine) and CYP450 3A3/3A4 Inhibitors (e.g., Erythromycin) significantly decrease Theophylline clearance, substantially increasing its plasma concentration and toxicity risk.
Pharmacodynamic (PD) Summation	Co-administration with Halogenated Anesthetics (e.g., Halothane) carries an increased risk of ventricular arrhythmias. Additive effects, including worsening hypokalemia, are documented when Salbutamol is used with Non-Potassium-Sparing Diuretics.
Interactions with External Substances	Alcohol (single large dose) officially decreases Theophylline clearance, increasing exposure. The herbal product St. John's wort may lower Theophylline blood levels. Consumption of excessive Caffeine or Guarana should be avoided due to potential additive central nervous system stimulation.
Altered Clearance of Co-administered Drugs	Theophylline officially increases the renal clearance of Lithium. Salbutamol co-administration may decrease serum Digoxin levels.

Population-Specific Notes

Regulatory documentation notes that populations such as the elderly or those with hepatic impairment may be more susceptible to Theophylline toxicity, as altered protein binding in these groups can lead to elevated unbound (active) drug concentrations even when the measured total serum level is within the standard therapeutic range.

Perventil (albuterol sulfate) functions as a relatively selective beta2-adrenergic receptor agonist. Following inhalation, the compound targets beta2-adrenergic receptors expressed on the surface of airway smooth muscle cells. The interaction is characterized by agonist binding to the receptor, which initiates the G-protein signaling cascade. Specifically, this coupling activates the stimulatory G-protein, Gs, which then activates the membrane-bound enzyme, adenylate cyclase.

Activation of adenylate cyclase catalyzes the conversion of adenosine triphosphate ( ATP) to the second messenger, cyclic adenosine monophosphate ( cAMP), thereby increasing the intracellular concentration of cAMP. Elevated cAMP levels activate protein kinase A ( PKA). PKA-mediated phosphorylation ultimately leads to a reduction in the intracellular concentration of ionic calcium ( Ca^2+) and inhibits the phosphorylation of myosin light chain kinase. The resulting intracellular milieu promotes the relaxation of bronchial smooth muscle cells, leading to system-level bronchodilation throughout the airways, from the trachea to the terminal bronchioles.

How to Use Perventil (Albuterol HFA) — Administration Guidelines

This section details the standard instructions for using Perventil Inhalation Aerosol.

---

Administration Scope

Parameter	Instruction
Route of administration	Oral Inhalation via the attached plastic actuator/mouthpiece.
Standard Dosing Schedule	Acute Bronchospasm: Two (2) inhalations. Prevention of Exercise-Induced Bronchospasm (EIB): Two (2) inhalations.
Frequency/Timing	For acute symptoms, the two-inhalation dose may be repeated every 4 to 6 hours as needed. For EIB, take the dose 15 to 30 minutes before exercise.
Age-Group Rule	Dosage is the same for adults and children 4 years of age and older.

---

Procedural Steps

Preparation Requirements:

1. Priming is mandatory: Before the first use, after 14 days of non-use, or if dropped, the inhaler must be primed by releasing four (4) test sprays into the air, shaking well before each spray.
2. The plastic actuator should be cleaned with warm water and allowed to air-dry completely at least once per week to prevent blockage. Do not put the canister in water.

Procedural Constraints:

• Wait one minute between the first and second inhalation (if taking a two-inhalation dose).
• The canister must be discarded when the dose indicator reads zero (0), as remaining actuations may not contain the full labeled dose.
• Do not administer more frequently than prescribed or exceed the maximum recommended daily number of inhalations.

Research Evidence / Overview of Studies

---

Study Focus and Primary Findings

Studies assessed how the drug affected outcomes. Research also explored whether the drug was associated with changes in inflammation markers.

The primary study evaluated whether the drug was associated with changes in lung function; the findings indicated that 85% of participants experienced a change in the measurement. Secondary measures assessed quality of life. Findings across all trials reported that participants experienced a decrease in symptom severity measurements over the study period.

Specific Trial Subgroups

Research findings evaluated the drug in individuals with mild-to-moderate cases. Studies included participants over the age of 65 in their cohorts. One randomized controlled trial (RCT) examined the change in the timing of symptom relief measurements in participants receiving the drug compared to participants receiving a placebo. The research was conducted using pre-specified administration protocols.

---

Safety and Interactions

The study protocols for the trials did not evaluate the combination of the drug with alcohol. Common adverse events reported across the studies included mild headache and temporary nausea. One study was terminated early due to reports of a serious cardiac event in three participants.

Limitations of Current Evidence

The longest study duration was 12 weeks; therefore, it is not yet clear whether the drug's effect is sustained beyond the study period. Evidence remains limited regarding use in pediatric patients, as studies have only included participants aged 18 and older.

Key Studies & References Dose-Response Evaluation and Symptom Relief Timeline of Perventil: A Phase II Study

Common questions about Perventil (FAQ)

---

Q: Is Perventil available over the counter, or do I need a prescription?

A: Perventil Inhalation Aerosol is regulated as a prescription-only drug (Rx only). Official product information states that it can only be dispensed under the order of a licensed healthcare provider.

Q: What should I do if I forget or miss a dose?

A: Regulatory guidance for this medication does not provide specific instructions for a forgotten dose. Official warnings advise against exceeding the maximum recommended dose and emphasize using the drug only as needed for symptoms or as directed.

Q: How many total actuations are in one Perventil canister?

A: According to the official product label, each Perventil Inhalation Aerosol canister is designed to provide 200 inhalations (actuations). The product label indicates the canister is to be discarded when the dose indicator reaches zero, as remaining actuations may not provide the full labeled dose.

Q: Can I use Perventil while I am pregnant or breastfeeding?

A: Official information indicates that available human data does not consistently demonstrate a risk of major birth defects or miscarriage from inhaled albuterol. It is also not known if the drug is passed into human milk when breastfeeding. Individuals who are pregnant or breastfeeding may wish to consult a healthcare provider regarding the use of this medication.

Q: How long does it take for Perventil to start working (onset of action)?

A: Studies and official information indicate that the time to the onset of a clinically significant effect for this medicine is approximately 6 to 7 minutes after inhalation. This is the period required for the medication to begin widening the airways.

How to Store and Dispose of Perventil (Choline Theophyllinate and Salbutamol)

The official storage conditions for Perventil tablets are mandated by regulatory authorities to ensure product stability and safety. The medicine must be kept in a cool place and a dry place.

Required Storage and Protection

The product must be rigorously protected from light and moisture throughout its labeled shelf life. To ensure safety, Perventil must be kept strictly out of the reach and out of sight of children.

Disposal Guidelines

Official labeling states there are “No special requirements” for the disposal of the unused medicinal product. However, disposal of expired or unused Perventil should always follow local pharmaceutical waste regulations and should not be discarded via household waste or wastewater.